Nicole Ciffone, NP
Acute Care · Tucson, AZNPI 1750369500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,402 of the $162,145 with a category attached, or 68.1%. 30 manufacturers reported payments, led by Lilly USA, LLC at 59.9% of the total. 2025 is the largest year on record at $62,731, 6.1 times the $10,263 reported in 2021. Among acute care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $256.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$97K
- Regeneron Healthcare Solutions, Inc.$30K
- Amgen$20K
- Novartis$6K
- AstraZeneca$4K
- Amarin Pharma, Inc.$817
- plus $4K from 24 others
Across 3 payments — averaging $4299.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- Chiesi USA, Inc.$250
What the payments were for
- Consulting fees$8,5295%
- Speaking & faculty fees$110,40268%
- Travel & lodging$31,29219%
- Food & beverage$11,8517%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 249 | $97,069 |
| Regeneron Healthcare Solutions, Inc. | 83 | $29,778 |
| Amgen | 80 | $20,221 |
| Novartis | 82 | $5,652 |
| AstraZeneca | 15 | $4,459 |
| Amarin Pharma, Inc. | 6 | $817 |
| Esperion Therapeutics, Inc. | 9 | $772 |
| Merck | 22 | $446 |
| Ionis Pharmaceuticals, Inc. | 2 | $408 |
| Abbott | 16 | $293 |
| Kestra Medical Technology Services, Inc. | 2 | $290 |
| Regeneron | 5 | $282 |
| Boehringer Ingelheim | 9 | $250 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $210 |
| Boston Scientific | 4 | $208 |
| Novo Nordisk | 5 | $202 |
| Johnson & Johnson | 11 | $174 |
| Kowa Pharmaceuticals America, Inc. | 7 | $146 |
| Astellas Pharma US Inc | 3 | $98 |
| Actelion Pharmaceuticals US, Inc. | 1 | $96 |
| Pfizer | 5 | $68 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Biotronik Inc. | 1 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Medtronic | 1 | $24 |
| Baxter Healthcare | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Itamar Medical Inc | 1 | $8 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$162,145 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 424 | $457,202 |
| Praluent PenAlirocumab | 72 | $70,047 |
| MounjaroTirzepatide | 37 | $65,692 |
| VascepaIcosapent Ethyl | 33 | $29,672 |
| NexlizetBempedoic Acid/Ezetimibe | 26 | $25,489 |
| JardianceEmpagliflozin | 11 | $19,456 |
| NexletolBempedoic Acid | 24 | $19,035 |
| OzempicSemaglutide | 11 | $14,931 |
| LivaloPitavastatin Calcium | 18 | $14,910 |
| Pitavastatin Calcium | 26 | $7,090 |
| Ezetimibe | 172 | $3,431 |
| Rosuvastatin Calcium | 206 | $2,672 |
| Pravastatin Sodium | 16 | $155 |
| Metformin Hcl ErMetformin Hcl | 11 | $114 |
| Atorvastatin Calcium | 27 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $97,069 | $65,69237 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $772 | $44,52450 claims |
| Boehringer IngelheimJardiance | $250 | $19,45611 claims |
| Novo NordiskOzempic | $202 | $14,93111 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $146 | $14,91018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 acute care providers in Arizona.
Other acute care in Tucson
- Francisco MartinezTucson$10K
- Sabrina GreeneTucson$10K
- Resel VillanuevaTucson$8K
- Sydni BurkeTucson$8K
- April WeaverTucson$6K
- Susan BurnsTucson$6K
- Kristy KeatingTucson$6K
- Brenda MitchellTucson$5K
- Barbara MayerTucson$4K
- Shawn McKissickTucson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.